Bronchitis Treatment Market Report 2025

The bronchitis treatment market size has grown strongly in recent years. It will grow from $5.61 billion in 2024 to $5.94 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising air pollution levels, cigarette smoking epidemic, increased respiratory infections, environmental and occupational exposures, lifestyle factors.

The bronchitis treatment market size is expected to see strong growth in the next few years. It will grow to $7.95 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to advancements in respiratory medicine, expanded access to vaccination, tailored pediatric treatment approaches, precision medicine in respiratory care, global efforts to reduce smoking. Major trends in the forecast period include personalized treatment approaches, advancements in inhalation therapies, targeted therapies for specific bronchitis types, focus on prevention and vaccination, patient-centric care models,.

The rising prevalence of respiratory diseases is anticipated to drive the growth of the bronchitis treatment market in the future. Respiratory diseases encompass conditions that impact the lungs and other components of the respiratory system, affecting either the upper or lower respiratory tract. Various factors, including infections, allergens, irritants, and genetic factors, can contribute to these diseases. Treatments for bronchitis can vary based on the underlying cause and severity of the condition, involving the use of antibiotics, anti-inflammatories, and bronchodilators to facilitate airway dilation. For example, in November 2023, the Bureau of Labor Statistics, a US government agency, reported that in 2022, the illness rate among private industry employers increased to 45.2 cases per 10,000 full-time equivalent (FTE) workers, up from 37.7 cases in 2021. This rise was largely attributed to a greater incidence of respiratory illnesses, which escalated from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Consequently, the growing incidence of respiratory diseases is fueling the expansion of the bronchitis treatment market moving forward.

The growing aging population is poised to contribute to the expansion of the bronchitis treatment market. The aging population phenomenon, characterized by an increasing proportion of elderly individuals within a population, presents a demographic shift with implications for healthcare. Bronchitis treatment in the elderly offers various advantages, addressing both acute and chronic forms of the condition. Benefits include symptom alleviation, complication prevention, improved respiratory function, enhanced ease of breathing, elevated overall quality of life, and reduced hospitalization risks. Globally, the World Health Organization projects that by 2030, 1 in 6 people will be aged 60 or older, with the number doubling to 2.1 billion individuals by 2050. In the UK, the House of Commons Library forecasts a 24% rise in the senior population, reaching 17.4 million people by 2043. The increasing aging population emerges as a significant driver for the growth of the bronchitis treatment market.

Major players in the bronchitis treatment market are focusing on developing technologies like drug-device combination products to improve medication delivery effectiveness and enhance patient adherence to treatment plans. A drug-device combination product integrates a drug with a delivery device to amplify its therapeutic benefits. For example, in July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P. introduced Breyna. This inhalation aerosol is specifically designed for treating asthma and chronic obstructive pulmonary disease (COPD). It comprises a combination of active ingredients, including a long-acting beta-agonist (LABA) and a corticosteroid, which work synergistically to alleviate symptoms and diminish airway inflammation.

Major companies in the Bronchitis Treatment Market are advancing technologies like dry powder inhalers (DPI) to improve drug delivery precision, optimize dosing, and enhance the overall patient experience, making treatment more accessible and user-friendly for individuals with bronchitis. Dry Powder Inhalers (DPI) are devices that administer medication in a dry powder form directly to the lungs, enabling effective treatment of respiratory conditions. For instance, in November 2023, Lupin Limited, a pharmaceutical company based in India, introduced Vilfuro-G. This inhaler combines three active ingredients - vilanterol, fluticasone furoate, and glycopyrronium bromide - into a single device. This innovative formulation aims to provide comprehensive management of COPD symptoms by addressing inflammation, bronchoconstriction, and mucus production simultaneously.

In January 2022, Covis Pharma Group, a Switzerland-based specialty pharmaceutical company, made a strategic move by acquiring the respiratory portfolio of two medicines from AstraZeneca for $270 million. This transaction involved the acquisition of Eklira and Duaklir, positioning Covis to offer a comprehensive range of best-in-class treatments for allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD). The acquisition underscores Covis Pharma Group's capability to collaborate effectively and become a preferred partner for major pharmaceutical firms. AstraZeneca PLC, a UK-based pharmaceutical and biotechnology company and a co-developer of a vaccine against bronchiolitis, is the other party involved in this significant transaction. This strategic initiative demonstrates the ongoing efforts of major companies to expand their product portfolios and strengthen their positions in the competitive bronchitis treatment market.

Major companies operating in the bronchitis treatment market include AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Dr. Reddy’s Laboratories, Sanofi S.A., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Cipla Inc., Merck and Co. Inc., Bayer AG, Johnson & Johnson Private Limited, Viatris Inc., Lupin Ltd., Cadila Healthcare Limited, Lincoln Pharmaceuticals Ltd., Nephron Pharmaceuticals Corporation, Apotex Inc., Mylan N.V., Eli Lilly and Company, Abbvie, Hetero Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Alkem Laboratories Ltd., Wockhardt Ltd.

North America was the largest region in the bronchitis treatment market in 2024. The regions covered in the bronchitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bronchitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bronchitis treatment involves addressing the inflammation of the bronchial tubes, which results in excessive mucus production. Medications used for this treatment include bronchodilators, steroids, and antibiotics to alleviate symptoms.

The treatment is designed to address both acute and chronic bronchitis, utilizing various approaches such as medications and oxygen therapy. Acute bronchitis is a contagious viral infection leading to inflammation in the bronchial tubes. These treatments are typically available through diverse distribution channels such as online pharmaceutical stores, retail pharmacies, and hospital pharmacies.

The bronchitis treatment market research report is one of a series of new reports that provides bronchitis treatment market statistics, including bronchitis treatment industry global market size, regional shares, competitors with a bronchitis treatment market share, detailed bronchitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the bronchitis treatment industry. This bronchitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bronchitis treatment market includes revenues earned by entities by providing vaccines surgery, and pulmonary rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.